by Marisa Wexler, MS | Nov 19, 2025 | Myeloma News
A committee of the World Health Organization (WHO) has approved an international nonproprietary name (INN) for Anixa Biosciences’ experimental cell therapy for ovarian cancer. The therapy, which is already in clinical testing, will now carry the INN liraltagene...
by MM360 Staff | Nov 19, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Nov 18, 2025 | Myeloma News
Regulators in the U.S. and Europe have approved updates to the prescribing information for Carvykti (ciltacabtagene autoleucel), a cell therapy used to treat hard-to-manage myeloma. The updates include survival data from the ongoing CARTITUDE-4 (NCT04181827) Phase 3...
by Marisa Wexler, MS | Nov 17, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has approved ziftomenib to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 gene mutation who have no satisfactory alternative treatment options. The once-daily oral therapy,...
by Marisa Wexler, MS | Nov 14, 2025 | Myeloma News
Capsovision is requesting that the U.S. Food and Drug Administration (FDA) expedite the development of its CapsoCam UGI capsule endoscopy system as a potential tool for detecting early-stage pancreatic cancer. The CapsoCam system is similar to a large pill containing...
by Margarida Maia, PhD | Nov 13, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, a treatment candidate from Purdue Pharma that aims to extend survival for people with malignant gliomas, the developer announced. Gliomas are a group of tumors that form...
